A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy

Principal Investigator

Julie Graff

Study Purpose

To find out how effective the study drug (Abiraterone Acetate) and prednisone alone or in combination with degarelix or degarelix alone on hormone sensitive prostate cancer, and how well participant's prostate-specific antigen (PSA) response to the therapy, and to find out the side effects of the study drug and prednisone in combination with degarelix.

Medical Condition(s)

Prostate cancer

Eligibility Criteria

- Subjects must have confirmed adenocarcinoma of the prostate cancer and is currently progressing by PSA
- Subjects must have adequate kidney and liver function.
- Subjects have not had any prior hormonal thearpy.
- Subjects have not had any brain metastases or evidence of metastatic disease by CT or bone scan; however, paticipants with metastases to pelvic lymph node might be eligible.

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

Up to 3 years, including screening and post-treatment follow-up period.

Minors Included



Clinical Trials Information Line: Phone 503-494-1080 or


Memorial Sloan-kettering Cancer Center

Recruitment End


Compensation Provided


Go Back